2017
Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Serrao GW, Lansky AJ, Mehran R, Stone GW. Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2017, 121: 678-683. PMID: 29394998, DOI: 10.1016/j.amjcard.2017.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsBiomarkersCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsRecombinant ProteinsRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionStentsStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIAcute Myocardial Infarction trialMyocardial Infarction trialElevation myocardial infarctionHarmonizing OutcomesLVEF improvementMyocardial infarctionLower baseline left ventricular ejection fractionLeft ventricular ejection fraction improvementBaseline left ventricular ejection fractionGlycoprotein IIb/IIIa inhibitorsVentricular ejection fraction improvementMyocardial Infarction 3 flowIIb/IIIa inhibitorsEjection fraction improvementHalf of patientsPercutaneous coronary interventionVentricular ejection fractionPredictors of improvementPrespecified substudyPrimary stentingAngiographic predictors
2016
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleeding
2012
Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction
Brener SJ, Cristea E, Lansky AJ, Fahy M, Mehran R, Stone GW. Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction. Circulation Cardiovascular Interventions 2012, 5: 563-569. PMID: 22828707, DOI: 10.1161/circinterventions.112.969022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAntithrombinsCoronary AngiographyCoronary CirculationDrug-Eluting StentsElectrocardiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionObserver VariationPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionPredictive Value of TestsPrognosisRecombinant ProteinsTubulin ModulatorsConceptsPrimary percutaneous coronary interventionMyocardial blush gradeST-segment elevation myocardial infarctionPercutaneous coronary interventionTIMI flowMyocardial infarctionCoronary interventionMBG 2Post-PCI myocardial blush gradePost-PCI TIMI 3 flowPrimary PCIFinal myocardial blush gradeFinal TIMI flow 0Pre-PCI TIMI flowCore laboratory assessmentFinal TIMI flowRelative prognostic utilityTIMI flow 0Myocardial infarction (TIMI) flowTIMI 3 flowElevation myocardial infarctionImportant prognostic indicatorHarmonizing OutcomesMBG 0Reperfusion markerPrognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens
Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, Stone GW. Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens. Circulation Cardiovascular Interventions 2012, 5: 157-165. PMID: 22354934, DOI: 10.1161/circinterventions.111.963876.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overBiomarkersFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHumansKidney Failure, ChronicMaleMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsReference StandardsSurvival AnalysisTroponin TConceptsGlycoprotein IIb/IIIa inhibitorsAcute coronary syndromeBaseline troponin elevationChronic kidney diseaseMajor adverse cardiac eventsTroponin elevationMyocardial infarctionBivalirudin monotherapyMajor bleedingCKD patientsCoronary syndromeBaseline troponinKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsLong-term clinical outcomesBaseline cardiac troponinBaseline troponin levelsDifferent antithrombotic regimensAdverse cardiac eventsACS patientsACUITY trialAntithrombotic regimensComposite deathRandomization arm
2011
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 2011, 7: 905-16. PMID: 22157475, DOI: 10.4244/eijv7i8a144.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingMyocardial infarctionTF approachMajor adverse cardiovascular eventsNet adverse clinical eventsAdverse cardiovascular eventsEvent-free survivalAdverse clinical eventsPercutaneous coronary interventionImproved clinical outcomesAcute myocardial infarctionOne-year ratesRate of deathPaucity of dataComposite deathHORIZONS-AMICardiovascular eventsPrimary angioplastyAnticoagulation regimensCoronary interventionLong-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsEffect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis
Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW, Investigators H. Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. Journal Of The American College Of Cardiology 2011, 57: 2309-2316. PMID: 21636031, DOI: 10.1016/j.jacc.2011.01.038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMajor bleedingMyocardial infarctionCardiac mortalityAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsPrimary Percutaneous Coronary Intervention ResultsGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsElevation myocardial infarction patientsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBenefit of bivalirudinLate cardiac survivalProbable stent thrombosisPercutaneous coronary interventionTwo-year rateAcute myocardial infarctionMyocardial infarction patientsHORIZONS-AMISwitch patientsPrimary angioplastyControl patientsCoronary interventionImpact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials
Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials. JACC Cardiovascular Interventions 2011, 4: 654-664. PMID: 21700252, DOI: 10.1016/j.jcin.2011.02.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsFemaleHealth Status IndicatorsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial ReperfusionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRandomized Controlled Trials as TopicRecombinant ProteinsRisk AssessmentRisk FactorsTriageConceptsPercutaneous coronary interventionTIMI major bleedingPatient-level pooled analysisHORIZONS-AMI trialMajor bleedingBlood transfusionSubsequent mortalityRisk scoreHazard ratioIndependent predictorsPooled analysisGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsIIb/IIIa inhibitorsMajor bleeding ratesTIMI major bleedTIMI minor bleedingRespective hazard ratiosArtery bypass graftRisk score groupsHigh-risk groupRisk of patientsIsolated hematomasMajor bleedsLate mortalityResponse to Letters Regarding Article, “Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy”
Lansky A, Goto K, Fahy M, Cristea E, Mehran R, Stone GW, Feit F, Ohman EM, Alexander KP, White HD, Bertrand ME, Desmet W, Hamon M. Response to Letters Regarding Article, “Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy”. Circulation 2011, 123: e410-e411. PMID: 21648119, DOI: 10.1161/circulationaha.110.010306.Peer-Reviewed Original ResearchFrequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictors
2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskA Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal Of The American College Of Cardiology 2010, 55: 2556-2566. PMID: 20513595, DOI: 10.1016/j.jacc.2009.09.076.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overAngioplasty, Balloon, CoronaryCause of DeathConfidence IntervalsCoronary AngiographyCoronary Artery BypassElectrocardiographyFemaleFibrinolytic AgentsHemorrhageHeparinHospital MortalityHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsProbabilityProportional Hazards ModelsRisk AssessmentSeverity of Illness IndexSurvival AnalysisTreatment OutcomeConceptsAcute coronary syndromeInteger risk scoreMajor bleedingRisk scoreCoronary syndromeNon-coronary artery bypass graft surgerySubsequent mortalityCox proportional hazards regression modelArtery bypass graft surgeryProportional hazards regression modelsMultivariable logistic regression modelHORIZONS-AMI trialPractical risk scoreBypass graft surgerySimple risk scoreIndependent baseline predictorsTreatment-related variablesHazards regression modelsAppropriate treatment strategyLogistic regression modelsGraft surgeryHemorrhagic complicationsIdentifies patientsBlood transfusionLarge hematomaImpact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial)
Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 105: 1385-1394. PMID: 20451683, DOI: 10.1016/j.amjcard.2010.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAngioplasty, Balloon, CoronaryCombined Modality TherapyDrug Therapy, CombinationElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNeoadjuvant TherapyPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsRisk AssessmentSex FactorsSurvival AnalysisThrombolytic TherapyTreatment OutcomeConceptsST-elevation myocardial infarctionElevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline anemiaPercutaneous coronary interventionAdjunctive antithrombotic therapyMajor bleedingMyocardial infarctionAntithrombotic therapyCoronary interventionUnfractionated heparinST-segment elevation myocardial infarctionMultivariate analysisAcute Myocardial Infarction trialImpact of anemiaMyocardial Infarction trialOutcomes of patientsHarmonizing OutcomesCardiac mortalityCause mortalityLate mortalityPrimary PCIClinical outcomesPredictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage
Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. Circulation 2010, 121: 853-862. PMID: 20142447, DOI: 10.1161/circulationaha.109.877944.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAcute coronary syndrome patientsCoronary syndrome patientsComposite ischemiaCoronary syndromeAngiographic screeningCoronary ectasiaIschemic outcomesJeopardy scoreSyndrome patientsUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsAcute coronary syndrome populationPrevious percutaneous coronary interventionIIb/IIIa inhibitorsComposite ischemic eventsEarly invasive approachAdverse cardiac eventsOutcomes of patientsPercutaneous coronary interventionPredictors of outcomeTraditional clinical parametersAcute CatheterizationBivalirudin therapyMajor bleedingThe relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban
2009
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications
Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation 2009, 121: 43-51. PMID: 20026777, DOI: 10.1161/circulationaha.109.878017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRecombinant ProteinsRetrospective StudiesRisk FactorsConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIndividual patient risk profileAcute coronary syndromePatient risk profileMajor bleedingMyocardial infarctionCoronary syndromeRisk profileHemorrhagic complicationsIndependent predictorsMortality rateUrgent Intervention Triage Strategy (ACUITY) trialAlternative antithrombotic regimensIndividual patient's riskRisk of deathCox regression modelTherapy of patientsSubsequent mortality ratesRelative treatment effectsAcute CatheterizationAntithrombotic regimensMajor bleedsAlternative pharmacotherapyStrategy trialOutcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMIGastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. Journal Of The American College Of Cardiology 2009, 54: 1293-1302. PMID: 19778672, DOI: 10.1016/j.jacc.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAge FactorsAgedAngioplasty, Balloon, CoronaryAnticoagulantsClopidogrelCoronary Artery BypassFemaleGastrointestinal HemorrhageHeparinHirudinsHumansIncidenceIschemiaLength of StayMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk AssessmentSex FactorsStentsThrombosisTiclopidineConceptsAcute coronary syndromeGastrointestinal bleedingACUITY trialComposite ischemiaCardiac mortalityCause mortalityCoronary syndromeHigh-risk acute coronary syndromesStudy drug administrationOpen-label usePotential hemorrhagic complicationsST-segment deviationAntiplatelet medicationsBaseline anemiaHemorrhagic complicationsIschemic complicationsIndependent predictorsClinical outcomesMultivariable analysisStent thrombosisMyocardial infarctionSerious conditionPatientsDrug AdministrationOlder age